Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | Pre-clinical studies in CTCL

Jan P. Nicolay • 15 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases

Jan P. Nicolay, MD, Ruprecht Karls University of Heidelberg, Mannheim, Germany, comments on recent pre-clinical studies in the field of cutaneous T-cell lymphoma (CTCL) which have identified novel treatment targets including CXCL-CXCR interactions and CD30. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Jan P. Nicolay

0:51
Key updates from EORTC CL 2021
Jan P. Nicolay • 15 Oct 2021
0:57
Novel targets in the treatment of CTCL
Jan P. Nicolay • 15 Oct 2021
1:20
DMF therapy for CTCL
Jan P. Nicolay • 15 Oct 2021
1:08
The benefits of combination approaches in CTCL
Jan P. Nicolay • 15 Oct 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals